Drug Recall: Simvastatin tablets due to manufacturing deviations
RemedyRepack Inc. is recalling Simvastatin 40 mg tablets nationwide due to manufacturing deviations. The voluntary recall was initiated in March 2023.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This recall meets the rubric criterion for Score 2 (Moderate): a voluntary precautionary recall with FDA Class II classification and no reported illnesses or injuries.
Plain-English summary
RemedyRepack Inc. is recalling Simvastatin 40 mg tablets distributed nationwide within the United States. The recalled product was packaged in two formats: 30-count bottles (NDC 70518-0060-01) and 90-count bottles (NDC 70518-0060-00).
The recall was initiated due to current Good Manufacturing Practice (cGMP) deviations. The specific nature of these manufacturing deviations was not disclosed in the FDA notice.
Multiple lot numbers are affected, with expiration dates ranging from July 2023 through March 2025. The recall was voluntary and initiated by RemedyRepack Inc. on March 20, 2023, with the FDA classifying it as Class II on March 31, 2023. The recall was terminated on October 19, 2023.
Consumers with affected Simvastatin tablets should consult their healthcare provider or pharmacist about whether their medication may be involved and what steps to take.
The recalled product
- Product
- Simvastatin 40 mg tablets, packaged in a) 30-count bottles (NDC 70518-0060-01) and b) 90-count bottles (NDC 70518-0060-00), Rx only, Repackaged by: RemedyRepack Inc., Indiana, PA 15701
- Manufacturer
- RemedyRepack Inc.
- Category
- Drug — Statin
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot # a): J0656821-103122
- Exp. Date 11/30/2023
- J0638547-080922
- Exp. Date 08/31/2023
- J0633575-071822
- Exp. Date 07/31/2023 Lot #: b): B1965081-111622
- Exp. Date 03/31/2025
- B1857922-091922
- B1765298-071322
- B1786319-072922
- B1706842-053122
- Exp. Date 04/30/2023
- B2003311-120822
- Exp. Date 04/30/2025
- B1955679-111122
- Exp. Date 02/28/2025
- B1878942-092922
- Exp. Date 11/30/2024
- B1823203-082622. Exp. Date 10/31/2024
- B1706843-053122
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 14 recalled by RemedyRepack Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 14 products in this recall →Related recalls
Same manufacturer · RemedyRepack Inc.
See all →- ModerateClindamycin HCl Capsule 300 mg repackaged by RemedyRePack Inc.
FDA (Drugs) · 2025-05-14
- ModerateClindamycin HCl 300 mg Capsule Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-30
- HighCarvedilol 25 mg tablets recalled due to N-nitroso impurity above limit
FDA (Drugs) · 2025-02-12
- HighDuloxetine delayed-release capsules recalled due to manufacturing impurity
FDA (Drugs) · 2025-01-01
- HighPotassium Chloride Extended Release Capsules Recalled for Dissolution Defect
FDA (Drugs) · 2024-07-24
Same hazard · manufacturing deviation
See all →- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Vancomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateSynjardy XR Tablets Recalled Due to Manufacturing Deviations
FDA (Drugs) · 2026-07-08
- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- ModerateFentanyl Citrate Injectable Solution Recalled for cGMP Deviations
FDA (Drugs) · 2026-05-06